Company intelligence / Profile preview
Alpha Biopharma (Jiangsu) Co., Ltd.
Shanghai, Shanghai, Chinaalphabiopharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Alpha Biopharma's lead candidate Zorifertinib (EGFR TKI) is first-in-class in China with 100% blood-brain barrier penetration for CNS metastases of EGFR-mutant NSCLC, and is supported by national innovation programs. Universal CAR-T and Memory NK cell programs are in early clinical stages, with WU-CART-007 in Phase 1/2 for CD7-positive lymphomas[1][5][7].
- Therapeutic areas
- OncologyHematology
- Modalities
- Small moleculeUniversal CAR-TCIK therapyiNKT cell therapyCell therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Wugen Inc.
Beyond the preview
Go deeper on Alpha Biopharma (Jiangsu) Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alpha Biopharma (Jiangsu) Co., Ltd..